The BRAF mutation is a rare mutation. It is only reported in about 3% to 5% of all NSCLC cases. It is found almost exclusively in the adenocarcinoma NSCLC subtype of lung cancer, but it occurs in ...
HealthDay on MSN23h
Ultra-Rapid Molecular-Genetic Assays Feasible for Tumor Classification During SurgeryIntraoperative ultra-rapid droplet digital polymerase chain reaction (UR-ddPCR) can identify tumor genetic subtype and ...
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials ...
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Con ...
News Medical on MSN1d
Co-Occurring Mutations Drive Therapy Resistance in KRAS G12C CancersColorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic ...
Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectivelyEnded 2024 with ...
Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...
A novel tool for rapidly identifying the genetic “fingerprints” of cancer cells may enable future surgeons to more accurately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback